Onconetix Inc Ordinary Shares ONCO 深 沪
等待开盘 08-14 09:30:00 美东时间
3.10
+0.140
+4.73%
华盛通- 最 高3.20
- 今 开2.92
- 成交量 13.16万股
- 最 低 2.91
- 昨 收 2.96
- 总市值 161.79万
- 52周最高 552.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.61
- 委 比 50.00%
- 总股本 52.19万
- 历史最高 309060.00
- 量 比 0.59
- 振 幅 9.80%
- 历史最低 2.91
- 每 手 1
- 风险率 175.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Onconetix Director Resignation Amid Financial Adjustments
An announcement from Onconetix ( ($ONCO) ) is now available. On August 6, 2025,...
08-13 04:45
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Psyence Biomedical (NASDAQ:PBM) stock rose 62.6% to $8.78 during Thurs...
07-31 20:08
Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using Real-World Data for External Control Arms
Onco-Innovations subsidiary, Inka Health, partners with OneMedNet to lead a data analytics initiative improving cancer therapy development. The project uses OneMedNet's patient data to develop external control arms, potentially reducing costs and timelines for clinical trials. Inka Health will deploy its SynoGraph platform, leveraging AI and causal inference, focusing on non-small cell lung cancer. This collaboration aims to accelerate treatment ...
07-31 12:00
Onco-Innovations’ Inka Health to Lead AI-Driven Oncology Project with OneMedNet
Onco-Innovations Ltd. ( ($TSE:ONCO) ) just unveiled an announcement. Onco-Innov...
07-31 06:37
Oncopeptides Partners with SD Pharma to Expand Pepaxti Reach in Spain
Oncopeptides AB ( ($SE:ONCO) ) has provided an update. Oncopeptides AB has anno...
07-30 15:16
Oncopeptides’ Real-World Data Accepted at IMS Annual Meeting
Oncopeptides AB ( ($SE:ONCO) ) has issued an announcement. Oncopeptides AB anno...
07-23 14:59
Onco-Innovations Appoints Renowned Chemist to Advisory Board
Onco-Innovations Ltd. ( ($TSE:ONCO) ) has shared an update. Onco-Innovations Li...
07-22 02:32
福特别克正式入局增程式混动！
（来源：车联新生态） 在最新一期工信部申报图上，获取到了一组江铃福特旗下福特烈马新能源的新车申报图，新车将会提供纯电和增程两种动力。目前，福特官方已经发布了最新...
07-18 09:05
Onconetix And Ocuvex Therapeutics Announce Merger Agreement; Onconetix To Acquire All Issued And Outstanding Equity Interest Of Ocuvex, Ocuvex Equity Holders To Receive Onconetix Common Stock Equal To 90% Of Issued And Outstanding Equity Interest In Combined Co.
Pursuant to the Merger Agreement, Onconetix will acquire all of the issued and outstanding equity interests of Ocuvex and, in consideration for their equity interests, Ocuvex equity holders will receive newly-issued
07-16 20:20
Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement
Onconetix, Inc. and Ocuvex Therapeutics, Inc. have entered into a definitive merger agreement. Onconetix will acquire all of Ocuvex's equity interests in exchange for newly-issued shares, giving Ocuvex equity holders 90% ownership in the combined company. Onconetix shareholders retain 10%. The merger is expected to close in the fourth quarter of 2025, subject to regulatory and shareholder approvals. Both companies' boards have approved the transa...
07-16 12:17
